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Therapy-related myelodysplastic syndromes
(t-MDS) occur in patients exposed to genotoxic
chemotherapy, irradiation, or both. At least 20,000
cases of MDS were diagnosed in the U.S. in 2008, of
which approximately 10% were therapy-related. Be-
cause objective diagnostic criteria for t-MDS are lack-
ing, this likely underestimates the true incidence.
Cases are attributed to previous therapy based on cir-
cumstantial evidence, including the (1) presence of typ-
ical clonal cytogenetic abnormalities, (2) significant
exposure to leukemogenic therapy (ie, at least 1 cycle),
and (3) sufficient latency from exposure to diagnosis
of t-MDS (ie, at least 6 months).
Alkylating agents are the principal cause of t-MDS.
The syndrome was first recognized in the treatment of
Hodgkin disease (HD), in which a relationship be-
tween alkylator dose and risk of t-MDS/acute myelog-
enous leukemia (AML) was established [1,2]. This
thinking has been extrapolated to the autologous
stem cell transplantation (SCT) population as a poten-
tial explanation for t-MDS rates as high as 10% [3].
There are several sources of bias in these retrospective
reports, because SCT recipients often are heavily pre-
treated and have increased survival after transplanta-
tion (and thus have more years ‘‘at risk’’ for t-MDS).
Indeed, there is evidence of clonal abnormalities at
the time of transplantation in some patients who subse-
quently develop t-MDS/AML [4,5]. Nevertheless, atDivision of Oncology, Stem Cell Biology Section, Wash-
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with follicular lymphoma demonstrated a higher rate
of t-MDS/AML in the high-dose chemotherapy arm
compared with the conventional-dose chemotherapy
arm (7% vs 0%; P5 .014), suggesting that the trans-
plantation procedure contributes directly to leukemia
risk [6]. In most series, higher rates of t-MDS/AML
have been reported in patients conditioned with total
body irradiation (TBI)-containing regimens [3].
Therapy-related leukemia also can be caused by
exposure to topoisomerase II inhibitors.These patients
typically present with t-AML without a preceding
MDS phase. Because most patients receive combina-
tion chemotherapy, it often is impossible to assign
blame to a particular agent. Regardless of the cause,
t-MDS/AML has an inferior prognosis compared
with de novo disease [7]. The only curative option is
allogeneic SCT [8]. In this sense, this disease is unique
among hematopoietic malignancies, in that hemato-
poietic SCT is both an important cause and the only
available cure.GENETICS
Recurring genetic abnormalities in t-MDS have
been defined across the full spectrum of analytical plat-
forms from cytogenetics to gene resequencing. Loss of
material from chromosomes 5 and/or 7 is detectable in
up to 70% of t-MDS/AML patients, often with other
abnormalities in a complex karyotype [9]. The same
pattern of cytogenetic abnormalities occurs in de
novo MDS, but at a much lower frequency [10].
Through the work of many investigators, the mini-
mally deleted regions on chromosomes 5 and 7 have
been mapped, and the residual alleles have been exam-
ined for loss of heterozygosity. We performed a com-
prehensive analysis of the minimally deleted region on
5q31.2 using array comparative genomic hybridiza-
tion, gene resequencing, and expression profiling. All
28 genes in the region on the unaffected chromosomeS45
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with no gene consistently silenced [11]. This study and
others suggest that multiple genes on 5q31.2 contrib-
ute to t-MDS by haploinsufficiency. Similarly, no
single culprit has been identified on 7q, raising the
possibility that a similar mechanism may apply.
Mutational profiling of individual candidate genes
has revealed unique features of t-MDS. Point muta-
tions in TP53, RUNX1, and K/NRAS are more com-
mon in t-MDS compared with de novo MDS
(approximately 25% vs 10%, 20% vs 10%, and 5%-
10% vs 5%, respectively), whereas mutations in
FLT3 are relatively underrepresented in t-MDS [12-
16]. Ongoing studies using transcriptome, whole
exome, and whole genome sequencing approaches
will provide an unbiased comparison of the genetic
landscape in t-MDS and de novo MDS.
In addition to these somatic changes, there may be
a genetic component to t-MDS susceptibility. Rare
familial cancer predisposition syndromes provide proof
of principle that inherited genetic variants can influence
the susceptibility to t-MDS/AML. For example, chil-
dren with neurofibromatosis-1 (NF1) are at 200- to
500-fold greater risk for developing myeloid malignan-
cies [17], and t-MDS can occur as a second malignancy
in adult NF patients exposed to alkylators [18]. In spo-
radic t-MDS/AML, candidate gene association studies
have focused on genes involved in drug detoxification
and DNA repair. More than 30 published studies have
examined the role of variants in the conjugating en-
zymes involved in phase IImetabolism. Ameta-analysis
criticized most of these studies for inadequate
sample size and population heterogeneity [19]. Associ-
ations with the deleted genotypes of the glutathione
S-transferases, GSTM1 and GSTT1, are mostly null.
Heterozygosity of the codon 105 polymorphism in
GSTP1 does appear to increase the risk of t-MDS/
AML (odds ratio [OR]5 2.66; 95% confidence interval
[CI]5 1.39-5.09) [20]. Inphase Imetabolism, thepoor-
metabolizer genotypes of CYP2C19 or CYP2D6 do not
appear to be associated with t-MDS/AML risk [21],
whereas reduced risk (OR5 0.07) was associated with
the variant allele in the 50 promoter of CYP3A4 [22].
Common polymorphisms in genes involved in the
response to drug-induced DNA damage also have
been implicated as risk factors for t-MDS/AML. Like
changes in genes involved in drug detoxification, the
relative risks associated with these variations are small
(generally, OR\ 2.0). Increased risk of t-MDS/AML
has been demonstrated with the Lys751Gln variant of
ERCC2 (XPD) [23], a single-nuclotide polymorphism
(SNP) in exon 13 of MSH2 [24], and reduced risk
associated with Arg399Gln of XRCC1 [25]. Many of
these associations have been difficult to replicate, as is
often the case in underpowered gene association stud-
ies. Sample size is an even greater constraint in
genome-wide association studies, although one recentpublication reported significantly more SNP associa-
tions in t-MDS/AML than would be expected by
chance [26].MODELS
Animal models of t-MDS provide platforms for
identifying both recurring mutations relevant for
human t-MDS and germline alleles that affect suscep-
tibility. For example, heterozygous Nf1 mutant mice
are susceptible to a spectrum of spontaneous and ther-
apy-induced myeloid malignancies that resembles the
pattern seen in humans with germline NF1 mutations
[27]. To identify novel genes associated with t-MDS
susceptibility, we performed a genome-wide screen
in mice. We exposed a large panel of inbred strains
to the prototypical alkylator N-nitroso-N-ethylurea
(ENU). Myeloid malignancies (eg, MDS, AML, gran-
ulocytic sarcoma) were induced in a strain-dependent
manner, supporting the notion that there is a genetic
component to susceptibility [28]. An F2 intercross be-
tween susceptible and resistant strains identified loci
associated with leukemia-free survival after ENU
[29]. Fine-mapping these intervals has identified can-
didate genes that currently are being tested for their
importance in t-MDS/AML susceptibility.
Several other mouse models of human MDS have
been generated using transgenic, gene targeting, and
retroviral transduction/transplantation approaches
[30]. Although these models recapitulate (to varying
degrees) the phenotype of human MDS, they are de-
fined by single genetic events and thus do not capture
the complexity of t-MDS. Similarly, other animal
models of MDS exist [30] that have not yet been
exploited to study t-MDS.BENCH TO BEDSIDE
Ongoing genomic studies in patients and animal
models of t-MDS will provide new information that
may be translated into strategies for improving the
treatment and prevention of t-MDS. Identification of
recurring mutations may provide new targets for ther-
apy. Translating knowledge of susceptibility alleles
into t-MDS prevention and control strategies may
prove more challenging. One approach would be to
identify patients with high-risk genotypes and tailor
their therapy accordingly. Many caveats apply here;
the effect size of the genotype must be relatively large,
the prevalence of variant alleles in the population
must be relatively high, and equipotent chemotherapy
must be available. Providing suboptimal chemotherapy
to a relatively large group of patients with potentially
curable malignancies to prevent a rare (albeit serious)
complication is an unacceptable trade-off. A second
strategy would be to offer intensive surveillance for
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genotype-specific relative risk.This effortwould be jus-
tified only if there was evidence that chemotherapy
delays progression from t-MDS to t-AML, or that early
transplantation improves overall survival (OS) in
t-MDS. A final approach, which is more speculative at
this stage, may prove most useful in the long term. It
is predicated on understanding the biochemical events
relevant for t-MDS initiation. If key regulatory factors
can be identified, then it may be possible to perturb
these factors during alkylator exposure in such a way
as to preserve antitumor efficacy, but reduce hemato-
logic toxicity. These approaches all require additional
work in animal models before clinical trials can be initi-
ated. Because patients undergoing autologous SCT are
at high risk, theymaybe an ideal population to recruit to
these trials. A successful outcome will certainly depend
on broad support from the transplantation community.ACKNOWLEDGMENTS
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